These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 28674866

  • 21. Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
    Kaufmann H.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):1-3. PubMed ID: 28623419
    [No Abstract] [Full Text] [Related]

  • 22. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H.
    Neurology; 2018 Oct 16; 91(16):e1539-e1544. PubMed ID: 30232253
    [Abstract] [Full Text] [Related]

  • 23. Utility of autonomic testing for the efficient diagnosis and effective pharmacological management of neurogenic orthostatic hypotension.
    Alam SB, Almardini W, Suleman A.
    BMJ Case Rep; 2019 Aug 20; 12(8):. PubMed ID: 31434666
    [Abstract] [Full Text] [Related]

  • 24. New developments in the management of neurogenic orthostatic hypotension.
    Biaggioni I.
    Curr Cardiol Rep; 2014 Nov 20; 16(11):542. PubMed ID: 25303896
    [Abstract] [Full Text] [Related]

  • 25. Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.
    Ho AH, Kinter CW, Wight J, Neelam AR, Krakow D.
    J Med Case Rep; 2020 Jun 20; 14(1):73. PubMed ID: 32560740
    [Abstract] [Full Text] [Related]

  • 26. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
    Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H.
    BMC Neurol; 2017 May 12; 17(1):90. PubMed ID: 28494751
    [Abstract] [Full Text] [Related]

  • 27. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
    Birkmayer W, Birkmayer G, Lechner H, Riederer P.
    J Neural Transm; 1983 May 12; 58(3-4):305-13. PubMed ID: 6420517
    [Abstract] [Full Text] [Related]

  • 28. Droxidopa in neurogenic orthostatic hypotension.
    Kaufmann H, Norcliffe-Kaufmann L, Palma JA.
    Expert Rev Cardiovasc Ther; 2015 May 12; 13(8):875-91. PubMed ID: 26092297
    [Abstract] [Full Text] [Related]

  • 29. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan 12; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 30. Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.
    Chen JJ, Han Y, Tang J, Portillo I, Hauser RA, Dashtipour K.
    Ann Pharmacother; 2018 Dec 12; 52(12):1182-1194. PubMed ID: 29972032
    [Abstract] [Full Text] [Related]

  • 31. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    Isaacson S, Vernino S, Ziemann A, Rowse GJ, Kalu U, White WB.
    J Am Soc Hypertens; 2016 Oct 12; 10(10):755-762. PubMed ID: 27614923
    [Abstract] [Full Text] [Related]

  • 32. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
    Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ, NOH301 Investigators.
    Neurology; 2014 Jul 22; 83(4):328-35. PubMed ID: 24944260
    [Abstract] [Full Text] [Related]

  • 33. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM.
    Drugs; 2015 Feb 22; 75(2):197-206. PubMed ID: 25559422
    [Abstract] [Full Text] [Related]

  • 34. Orthostatic hypotension for the cardiologist.
    Mar PL, Raj SR.
    Curr Opin Cardiol; 2018 Jan 22; 33(1):66-72. PubMed ID: 28984649
    [Abstract] [Full Text] [Related]

  • 35. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.
    Pérez-Lloret S, Quarracino C, Otero-Losada M, Rascol O.
    Expert Opin Pharmacother; 2019 Apr 22; 20(6):635-645. PubMed ID: 30730771
    [Abstract] [Full Text] [Related]

  • 36. Refractory orthostatic hypotension in a patient with a spinal cord injury: Treatment with droxidopa.
    Canosa-Hermida E, Mondelo-García C, Ferreiro-Velasco ME, Salvador-de la Barrera S, Montoto-Marqués A, Rodríguez-Sotillo A, Vizoso-Hermida JR.
    J Spinal Cord Med; 2018 Jan 22; 41(1):115-118. PubMed ID: 28114866
    [Abstract] [Full Text] [Related]

  • 37. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
    Elgebaly A, Abdelazeim B, Mattar O, Gadelkarim M, Salah R, Negida A.
    Clin Auton Res; 2016 Jun 22; 26(3):171-80. PubMed ID: 26951135
    [Abstract] [Full Text] [Related]

  • 38. Initiation of droxidopa during hospital admission for management of refractory neurogenic orthostatic hypotension in severely ill patients.
    McDonell KE, Preheim BA, Diedrich A, Muldowney JAS, Peltier AC, Robertson D, Biaggioni I, Shibao CA.
    J Clin Hypertens (Greenwich); 2019 Sep 22; 21(9):1308-1314. PubMed ID: 31368635
    [Abstract] [Full Text] [Related]

  • 39. Droxidopa for orthostatic hypotension: a systematic review and meta-analysis.
    Strassheim V, Newton JL, Tan MP, Frith J.
    J Hypertens; 2016 Oct 22; 34(10):1933-41. PubMed ID: 27442791
    [Abstract] [Full Text] [Related]

  • 40. Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges.
    Palma JA, Kaufmann H.
    Semin Neurol; 2020 Oct 22; 40(5):523-539. PubMed ID: 32906173
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.